Global Genome Editing Services Markets (2019-2030), Case Study, Patent Analysis, Academic Grant Analysis, Competitiveness Analysis, Company Profiles -

DUBLIN--()--The "Genome Editing Services Market-Focus on CRISPR 2019-2030" report has been added to's offering.

This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographical regions.

Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques. The biopharmaceutical pipeline includes close to 500 gene therapies, several of which are being developed based on the CRISPR technology.

Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based therapy was initiated. However, successful gene manipulation efforts involve complex experimental protocols and advanced molecular biology centered infrastructure. Therefore, many biopharmaceutical researchers and developers have demonstrated a preference to outsource such operations to capable contract service providers.

Consequently, the genome editing contract services market was established and has grown to become an indispensable segment of the modern healthcare industry, offering a range of services, such as gRNA design and construction, cell line development (involving gene knockout, gene knock-in, tagging and others) and transgenic animal model generation (such as knockout mice). Additionally, there are several players focused on developing advanced technology platforms that are intended to improve/augment existing gene editing tools, especially the CRISPR-based genome editing processes.

Given the rising interest in personalized medicine, a number of strategic investors are presently willing to back genetic engineering focused initiatives. Prevalent trends indicate that the market for CRISPR-based genome editing services is likely to grow at a significant pace in the foreseen future.

Report Scope

  • A detailed assessment of the current market landscape, featuring an elaborate list of over 80 companies that offer CRISPR-based genome editing services, and analyses based on a number of relevant parameters, such as type of gRNA service, availability of gRNA format, type of endonuclease, type of Cas9 endonuclease format, type of cell line engineering offering, type of cell line, type of animal model generation offering, availability of CRISPR libraries and important service provider details (year of establishment, company size and location of headquarters).
  • An insightful 2X2 representation, highlighting the competitiveness of various CRISPR-based genome editing service providers captured in our database (segregated across various peer groups based on company size), taking into consideration the supplier power and the specific genome editing capabilities (which include gRNA service(s), endonuclease service(s), cell line engineering service(s), animal model generation service(s) and availability of CRISPR library(s)) of different companies.
  • Elaborate profiles of key players (shortlisted based on strength of service portfolio), featuring a brief overview of the company, its financial performance (if available), a detailed description of its genome editing service offerings, recent developments and an informed future outlook.
  • An in-depth analysis of over 10,000 patents related to CRISPR technology that have been filed/granted, since 2006, highlighting key trends associated with these patents, across type of patent, publication year and application year, regional applicability, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed/granted), patent benchmarking and valuation.
  • A detailed analysis of close to 2,000 grants that have been awarded to support research projects related to CRISPR, between 2015 and 2019 (till September), highlighting important parameters, such as year of award, amount awarded, administering institute center, support period, funding mechanism, type of grant application, grant activity, type of recipient organization, regional distribution of recipient organization, prominent project leaders and emerging focus areas. It also features a detailed multivariate grant attractiveness analysis based on the amount awarded, support period, grant type and funding mechanism.
  • A discussion on the advanced technologies and systems that have been developed to improve CRISPR-related processes. It includes a list of companies that have developed such innovative technology platforms, along with details on a number of relevant parameters, such as year of establishment, company size, core expertise, location of headquarters and important technology specifications (including technology name, focus area and key features). In addition, it includes short profiles of key technology providers. Further, the chapter highlights a list of companies that offer CRISPR kits and CRISPR design tools.
  • An analysis highlighting potential strategic partners, segregated based on likelihood of entering into collaboration with CRISPR-based genome editing services providers. The analysis takes into consideration multiple relevant parameters, such as type of therapy, pipeline strength, pipeline maturity, company strength and therapeutic area.
  • A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall market.

One of the key objectives of the report was to evaluate the current opportunity and the future potential of CRISPR-based genome editing services market. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030.

In addition, we have segmented the future opportunity across [A] type of services offered (gRNA construction, cell line engineering and animal model generation), [B] type of cell line used (mammalian, microbial, insect and others) and [C] different geographical regions (North America, Europe, Asia Pacific and rest of the world).

To account for the uncertainties associated with the CRISPR-based genome editing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered

1. Preface

2. Executive Summary

3. Introduction

4. CRISPR-based Genome Editing Service Providers: Current Market Landscape

5. Company Competitiveness Analysis

6. Company Profiles

7. Patent Analysis

8. Academic Grant Analysis

9. Case Study: Advanced CRISPR-based Technologies/Systems and Tools

10. Potential Strategic Partners

11. Market Forecast

12. SWOT Analysis

13. Executive Insights

14. Appendix 1: Tabulated Data

15. Appendix 2: List of Companies and Organizations

Companies Mentioned

  • 302 Military Hospital of China
  • 4D Molecular Therapeutics
  • AAVogen
  • AbbVie
  • AbCheck
  • AbClon
  • Abeona Therapeutics
  • ACROBiosystems
  • Actus Therapeutics
  • Acucela
  • Adaptimmune Therapeutics
  • Adicet Bio
  • Advantagene
  • Advaxis
  • Adverum Biotechnologies
  • Adverum Biotechnologies
  • Aeon Therapeutics
  • Affiliated Hospital to Academy of Military Medical Sciences
  • Agency for Science, Technology and Research (A*STAR)
  • AgenTus Therapeutics
  • Agilent Technologies
  • Agilis Biotherapeutics
  • Akouos
  • Albert Einstein College of Medicine
  • Aldevron
  • Alex's Lemonade Stand Foundation
  • Allergan
  • Allife Medical Science and Technology
  • Allogene Therapeutics
  • AlphaVax
  • Altor Bioscience
  • American Gene Technologies
  • Amgen
  • Amicus Therapeutics
  • AMS Biotechnology
  • Anaeropharma Science
  • Analytical Biological Services
  • Anchiano Therapeutics
  • AnGes
  • Angionetics
  • Anhui Provincial Hospital
  • Animalab
  • Antagene
  • Antibody Design Labs
  • Apic Bio
  • Applied Biological Materials (abm)
  • Applied Genetic Technologies (AGTC)
  • Applied StemCell
  • and over 600 more...

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900